A histochemical technique for the detection of androgen binding in prostatic cancer was performed on specimens from 108 patients and compared with a biochemical method in a double blind study of 77. Statistical analyses showed a significant agreement between the two assay systems for the qualitative and quantitative presence or absence of specific androgen binding, as well as for the subcellular localization of binding in nucleus and/or cytoplasm. Although the number of cases studied was too small for statistical analysis, there appeared to be good correlation between histochemical androgen binding results and clinical response, or lack of response to hormonal manipulation in 20 patients with State C and Stage D carcinoma. No correlation was evident between androgen binding and tumor grade or clinicopathologic stage of disease of either histochemistry or biochemistry.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/1097-0142(19820301)49:5<984::aid-cncr2820490523>3.0.co;2-p | DOI Listing |
Ecotoxicol Environ Saf
January 2025
School of Public Health, Chongqing Medical University, Chongqing 400016, PR China. Electronic address:
Background: Neonicotinoids are the most widely used insecticide worldwide. Toxicological and epidemiological studies suggest that exposure to neonicotinoid may be linked to the development of childhood obesity. However, the evidence is limited.
View Article and Find Full Text PDFInt Urol Nephrol
January 2025
Faculty of Data Science and Information Technology, INTI International University, Nilai, Malaysia.
Background: Sex hormone-binding globulin (SHBG) plays a critical role in regulating androgen bioavailability and has been hypothesized to influence prostate cancer risk, though existing evidence is inconsistent. This systematic review and meta-analysis aimed to evaluate the association between SHBG levels and prostate cancer risk.
Methods: A comprehensive search was conducted across PubMed, Embase, and Web of Science for studies published up to December 1, 2024.
Adv Sci (Weinh)
January 2025
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200030, China.
Prostate cancer (PCa) is one of the most common malignancies for male individuals globally. Androgen deprivation therapy (ADT) initially demonstrated significant efficacy in treating PCa; however, most cases of PCa eventually progress to castration-resistant prostate cancer (CRPC), which becomes increasingly challenging to manage. Notably, the loss or disruption of primary cilia in PCa cells may play a critical role in the progression of the disease, and there are no reports on the role of circular RNAs in ciliogenesis.
View Article and Find Full Text PDFBiology (Basel)
December 2024
Department "Materno Infantile e Scienze Urologiche", University Sapienza, 00161 Rome, Italy.
The National Cancer Institute (NCI) recognizes the potential of technologies based on the use of nanoparticles (NPs) in revolutionizing clinical approaches to the diagnosis and prognosis of cancer. Recent research suggests that once NPs come into contact with the biological fluid of cancer patients, they are covered by proteins, forming a "protein corona" composed of hundreds of plasma proteins. The concept of a personalized, disease-specific protein corona, demonstrating substantial differences in NP corona profiles between patients with and without cancer, has been introduced.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Joint Surgery, Honghui Hospital, Xi'an Jiaotong University, Shaanxi, China.
Background: Emerging evidence suggests that sex hormones, particularly testosterone and sex hormone-binding globulin (SHBG), play a critical role in the pathophysiology of Rheumatoid arthritis (RA). However, the precise relationship between these hormonal factors and RA risk in men remains underexplored.
Methods: We conducted a cross-sectional analysis using data from the National Health and Nutrition Examination Survey (NHANES) 2011-2016.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!